Blood cancers

No room for complacency on molecular monitoring in CML

In the era of potent TKI therapy the importance of regular high-quality molecular monitoring is more important than ever in patients with chronic myeloid leukaemia (CML), Australian haematologists say. The availability of potent TKI agents that achieve good long-term disease control should not lull clinicians into a false sense of complacency about the need to monitor ...

Already a member?

Login to keep reading.

© 2021 the limbic